Metformin Weight Loss Off-Label UK 2026: Honest Guide

Metformin is one of the cheapest prescription medications in the UK — but its weight-loss effect is modest compared to GLP-1 injectables.

In 2026, a private prescription of Mounjaro at the 15mg dose runs to about £330 a month after Eli Lilly’s price hike last September. A box of metformin costs pennies a tablet. Honestly, the price gulf is the whole story here — that’s why the question keeps surfacing in 2026. The evidence does not justify treating metformin as a “cheap Wegovy”, but it does support a more nuanced position. This guide explains what metformin actually is, what the UK evidence shows for non-diabetic weight loss, when the NHS will and won’t prescribe it, when off-label use is reasonable, and how it sits next to Wegovy and Mounjaro in 2026. Sources are NICE, NHS England, MHRA, Diabetes UK and the BNF.

What metformin is and why it’s been linked to weight loss

Metformin is a first-line type 2 diabetes drug, used in the UK since 1957, and one of the most studied medications in modern medicine. Pharmacologically, it is a biguanide — its main action is reducing glucose production in the liver and improving the body’s sensitivity to insulin. Recent research suggests it also nudges gut microbiota and appetite signals, though those effects are smaller and less well characterised.

The weight-loss link wasn’t a marketing creation. It came from clinical observation: type 2 diabetes patients on metformin tended to lose a small amount of weight, in stark contrast to older diabetes drugs like sulphonylureas which routinely caused weight gain. Researchers asked the obvious follow-up question — does it produce weight loss in people without diabetes? That is the off-label story.

On the NHS the cost is striking — between £0.03 and £0.05 per tablet at list price. The doses titrates up slowly, usually 500mg once daily with food for the first week or two, then twice daily, working up to a maximum of 2000mg per day. Slow titration matters because metformin’s first-month side effects are stomach-related: nausea, diarrhoea, abdominal cramping. Most people settle within two to four weeks. For longer-term users, NHS practice is to check vitamin B12 every one to two years, because metformin can cause B12 deficiency over time.

What the actual evidence shows for weight loss

Let’s be honest about the numbers. Pooled meta-analyses show an average weight loss of one to three kilos over six to twelve months in non-diabetic adults taking metformin, with one frequently cited study reporting 2.1 kg compared to placebo. The effect varies enormously between individuals — some lose more, many lose nothing on the scales.

Context matters. The strongest results show up in adults with insulin resistance, prediabetes (HbA1c 42-47 mmol/mol) or PCOS — populations where metformin is essentially treating an underlying metabolic problem and weight loss is one of the consequences. In adults with normal insulin sensitivity, metformin alone simply does not produce meaningful weight loss. No transforming on the scales.

Prescribing decisions should be evidence-led — and the evidence on metformin for weight loss is modest at best.

When the NHS will and won’t prescribe metformin

The NHS line is simple. Metformin will not be prescribed purely for weight loss on the NHS, full stop. According to NICE NG28 and related Clinical Knowledge Summaries, metformin will be prescribed for several conditions where weight loss is a useful secondary effect — but not the primary reason.

For pure weight management, the NHS pathway is separate from metformin. Your GP can refer you to the NHS Digital Weight Management Programme. There are Tier 2 community programmes, Tier 3 specialist services for adults with BMI 35+ (or 32.5+ for some ethnic groups), and Tier 4 bariatric surgery in severe cases. Tier 3 services are also where NHS access to Wegovy and Mounjaro sits in 2026, under tight clinical criteria. Orlistat remains an NHS-licensed weight-loss drug for some patients.

Metformin vs Wegovy vs Mounjaro in 2026

Worth saying: metformin is not a cheap GLP-1, it is a different drug doing a different job. The 2026 numbers, drawn from MHRA approvals and current UK pricing:

These sit on entirely different parts of the spectrum. The GLP-1s are heavy-lift weight-loss medications. Metformin is a metabolic adjunct. If you’re choosing between paying £300 a month for Mounjaro and trying metformin off-label for £10, the maths is real but the effect sizes are not equivalent. For most adults wanting significant weight loss, the GLP-1s remain the right pharmacological tool, even though access and cost are real barriers in 2026. For adults with insulin resistance, prediabetes or PCOS who can’t access or afford GLP-1s, metformin is reasonable. Some private weight clinics layer the two — metformin for insulin resistance, GLP-1 for appetite — though that is a more involved clinical decision.

When off-label metformin for weight loss is reasonable

A private UK GP can prescribe metformin off-label if they judge it clinically appropriate. Off-label prescribing is legal in the UK, but the prescriber takes professional responsibility for the decision. The case is strongest in specific scenarios:

Where it probably won’t deliver: a metabolically healthy adult with normal insulin sensitivity wanting to lose 5-10 kg for cosmetic reasons. The evidence simply does not back meaningful weight loss in that group, and pursuing it can lead to GI side effects without the benefit. The honest framing is that metformin works because it improves a metabolic problem — if there is no metabolic problem, the lever doesn’t have much to pull on.

Side effects, B12 and who shouldn’t take metformin

Common short-term effects: nausea, diarrhoea, abdominal cramping. Slow-release (SR) versions are easier on the gut and often the better starting point if you’ve reacted badly to standard tablets before.

Long-term watch-out: vitamin B12 deficiency develops in about 6-30% of long-term users. NHS practice is to check B12 every one to two years and supplement if levels drop. According to BNF guidance and the British National Formulary 2025-26 edition, lactic acidosis is the rare but serious risk worth knowing about — almost exclusively in people with significant kidney impairment.

Contraindications:

• Severe kidney impairment (eGFR below 30).
• Severe liver impairment.
• Active severe infection or dehydration — temporary pause until recovered.

Cautions: pregnancy and breastfeeding require specialist input. Metformin is used in gestational diabetes and PCOS-related fertility care, but always under appropriate supervision. Don’t start metformin off-label without a UK-registered GP or pharmacist reviewing your medical history first.

Frequently Asked Questions

Will the NHS give me metformin for weight loss?

No. The NHS will not prescribe metformin purely for weight loss. It will be prescribed for type 2 diabetes, prediabetes, PCOS, gestational diabetes, and (sometimes, specialist-led) antipsychotic-induced weight gain. Any weight loss in those settings is a useful secondary effect, not the primary reason for prescribing.

How much weight will I lose on metformin?

On average, studies show 1-3 kg loss in non-diabetic adults over 6-12 months. Your individual response depends heavily on your metabolism — adults with insulin resistance or prediabetes do better. It is not comparable to the 14-21% body-weight loss possible with Wegovy or Mounjaro.

Is metformin a cheap alternative to Wegovy or Mounjaro?

It is vastly cheaper, but it is not an equivalent alternative. The weight loss effect is a fraction of what GLP-1 injectables achieve. It may be a useful option if you have a related metabolic condition such as prediabetes or PCOS and cannot access or tolerate GLP-1 drugs.

Can my GP prescribe metformin off-label?

A UK GP can legally prescribe any drug off-label if they consider it clinically appropriate and take professional responsibility. NHS GPs are unlikely to do so for weight loss alone given prescribing guidelines. Private GPs have more discretion and may prescribe off-label, often with a clearer monitoring plan.

How long does this take to actually work?

Off-label use for weight loss would typically be reviewed at 3-6 months. If there’s no meaningful weight loss or improvement in metabolic markers (HbA1c, fasting glucose, insulin) by then, continuing the prescription for that purpose isn’t justified. Long-term use only makes sense where there is genuine ongoing benefit.

Is metformin safe long-term?

For most adults, yes. It is one of the most-studied medications in modern medicine and has been used safely for type 2 diabetes for decades. The main long-term monitoring needs are vitamin B12 levels every one to two years and kidney function annually. Slow-release versions reduce GI side effects in long-term use.

The honest position: metformin is not a weight loss drug and is not licensed for weight loss in the UK. The NHS will not prescribe it for that indication alone. The evidence shows modest 1-3 kg average loss in non-diabetic adults, far below GLP-1 injectable results. If you have type 2 diabetes, prediabetes, or PCOS, talk to your GP about metformin on the NHS — it is widely used and weight loss can be a useful side benefit. If significant weight loss is your goal, ask about NHS Tier 3 access to Wegovy or Mounjaro, or budget for private GLP-1 prescriptions. Concrete first step: a GP HbA1c blood test to clarify your metabolic position.

If you do go private and off-label, only use a UK-registered prescriber, never an unverified online seller. For more on private costs and legal access routes, see our guide to cheapest Wegovy UK 2026 legal routes. You may also find our overview of seborrhoeic dermatitis scalp treatment UK useful if you’re managing multiple health concerns.